Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

The MG-ADL scale assesses the impact of gMG on daily ... At baseline, the median MG-ADL and Quantitative Myasthenia Gravis (QMG) total scores were 9 and 15, respectively; 88% of patients were ...

The primary end point was the change from baseline in the score on the Myasthenia Gravis Activities of Daily Living scale (MG-ADL; scores range from 0 to 24, with higher scores indicating greater ...

On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and placebo scores was -2.8 points (95% CI -3.9 to -1.7, P=0.001) at 52 weeks ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help ...

The MG-ADL scale ranges from 0 to 24 ... "We consistently hear from individuals living with myasthenia gravis who are hopeful for new treatment options that may help bring greater stability ...

In the full patient population, those who received inebilizumab had greater score improvement on the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) at 26 weeks than those who received ...

An antibody treatment from Immunovant and Roivant Sciences significantly reduced symptoms and disease activity in patients with generalized myasthenia gravis ... and activity scale called MG ...

The primary endpoint of the trial is safety and tolerability, and key secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis ...

The myasthenia gravis trial linked low and high doses of batoclimab to 4.7- and 5.6-point improvements, respectively, on the MG-ADL symptom and activity scale. Scores improved by 3.6 points in the ...